Biodesix Inc - Understand $bdsx stock

$BDSX Market Cap: $260.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$60.90M

TTM

Gross Margin

77.5%

TTM

Net Earnings

-$44.51M

TTM

Current Assets

$57.58M

Q2 2024

Current Liabilities

$17.55M

Q2 2024

Current Ratio

328.05%

Q2 2024

Total Assets

$115.8M

Q2 2024

Total Liabilities

$79.58M

Q2 2024

Book Value

$36.26M

Q2 2024

Cash

$42.22M

Q2 2024

P/E

-5.855

Sep 17, 2024 EST

Free Cash Flow

-$61.12M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018
Revenue	$49.09M	$38.21M	$54.51M	$45.56M	$24.55M	$20.43M
YoY Change	28.46%	-29.89%	19.64%	85.55%	20.18%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018
Revenue	$49.09M	$38.21M	$54.51M	$45.56M	$24.55M	$20.43M
Cost Of Revenue	$13.01M	$14.15M	$30.52M	$22.00M	$6.070M	$4.410M
Gross Profit	$36.08M	$24.06M	$23.99M	$23.56M	$18.48M	$16.03M
Gross Profit Margin	73.5%	62.96%	44.01%	51.72%	75.27%	78.46%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018
Selling, General & Admin	$67.39M	$61.46M	$50.52M	$34.86M	$30.64M	$25.90M
YoY Change	9.64%	21.67%	44.93%	13.77%	18.29%
% of Gross Profit	186.79%	255.47%	210.59%	147.95%	165.78%	161.57%
Research & Development	$9.988M	$13.10M	$12.79M	$10.82M	$10.47M	$8.190M
YoY Change	-23.77%	2.45%	18.22%	3.34%	27.81%
% of Gross Profit	27.69%	54.46%	53.31%	45.92%	56.65%	51.09%
Depreciation & Amortization	$3.328M	$3.597M	$3.178M	$2.900M	$2.790M	$1.740M
YoY Change	-7.48%	13.18%	9.59%	3.94%	60.34%
% of Gross Profit	9.22%	14.95%	13.25%	12.31%	15.1%	10.85%
Operating Expenses	$90.43M	$88.80M	$95.45M	$68.49M	$51.29M	$34.09M
YoY Change	1.84%	-6.96%	39.36%	33.53%	50.46%
Operating Profit	-$41.34M	-$50.59M	-$40.94M	-$22.93M	-$26.74M	-$18.06M
YoY Change	-18.28%	23.56%	78.51%	-14.24%	48.07%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018
Interest Expense	$9.536M	$8.072M	$4.508M	$7.604M	$3.008M	-$2.890M
YoY Change	18.14%	79.06%	-40.72%	152.79%	-204.08%
% of Operating Profit
Other Income/Expense, Net	-$10.80M	-$14.86M	-$2.219M	-$8.416M	-$3.985M	$390.0K
YoY Change	-27.29%	569.67%	-73.63%	111.19%	-1121.79%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018
Pretax Income	-$52.15M	-$65.45M	-$43.16M	-$31.35M	-$30.73M	-$26.17M
YoY Change	-20.32%	51.64%	37.67%	2.02%	17.42%
Income Tax	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$52.15M	-$65.45M	-$43.16M	-$31.35M	-$30.73M	-$26.17M
YoY Change	-20.32%	51.64%	37.67%	2.03%	17.41%
Net Earnings / Revenue	-106.23%	-171.27%	-79.18%	-68.81%	-125.15%	-128.1%
Basic Earnings Per Share	-$0.64	-$1.55	-$1.58
Diluted Earnings Per Share	-$0.64	-$1.55	-$1.577M	-$1.180M	-$1.171M	-$997.0K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018
Cash & Short-Term Investments	$26.28M	$43.09M	$32.71M	$62.10M	$5.300M	$5.900M
YoY Change	-39.0%	31.72%	-47.32%	1071.7%	-10.17%
Cash & Equivalents	$26.28M	$43.09M	$32.71M	$62.10M	$5.300M	$5.900M
Short-Term Investments
Other Short-Term Assets	$5.720M	$5.181M	$7.245M	$8.700M	$2.100M	$2.100M
YoY Change	10.4%	-28.49%	-16.72%	314.29%	0.0%
Inventory
Prepaid Expenses
Receivables	$7.679M	$5.065M	$3.656M	$15.30M	$5.300M	$1.900M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$39.68M	$53.33M	$43.61M	$86.10M	$12.70M	$9.900M
YoY Change	-25.6%	22.29%	-49.35%	577.95%	28.28%
Property, Plant & Equipment	$29.61M	$8.821M	$4.179M	$3.200M	$2.100M	$1.400M
YoY Change	235.7%	111.08%	30.59%	52.38%	50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.859M	$5.923M	$1.657M	$3.500M	$100.0K	$100.0K
YoY Change	15.8%	257.45%	-52.66%	3400.0%	0.0%
Total Long-Term Assets	$59.41M	$39.57M	$32.48M	$35.00M	$28.90M	$29.20M
YoY Change	50.14%	21.82%	-7.19%	21.11%	-1.03%
Total Assets	$99.10M	$92.91M	$76.10M	$121.1M	$41.60M	$39.10M
YoY Change
Accounts Payable	$2.929M	$1.685M	$1.662M	$9.000M	$1.700M	$900.0K
YoY Change	73.83%	1.38%	-81.53%	429.41%	88.89%
Accrued Expenses	$5.090M	$7.446M	$4.899M	$4.700M	$1.900M	$1.600M
YoY Change	-31.64%	51.99%	4.23%	147.37%	18.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$12.00M	$0.00
YoY Change				-100.0%
Long-Term Debt Due	$51.00K	$49.00K	$19.00K	$11.80M	$0.00
YoY Change	4.08%	157.89%	-99.84%
Total Short-Term Liabilities	$33.42M	$22.84M	$28.96M	$32.10M	$22.60M	$4.500M
YoY Change	46.31%	-21.14%	-9.78%	42.04%	402.22%
Long-Term Debt	$35.23M	$25.00M	$9.993M	$15.90M	$23.80M	$23.10M
YoY Change	40.88%	150.22%	-37.15%	-33.19%	3.03%
Other Long-Term Liabilities	$25.88M	$24.46M	$17.42M	$31.90M	$29.80M	$25.60M
YoY Change	5.8%	40.42%	-45.4%	7.05%	16.41%
Total Long-Term Liabilities	$61.10M	$49.46M	$27.41M	$47.80M	$53.60M	$48.70M
YoY Change	23.53%	80.45%	-42.66%	-10.82%	10.06%
Total Liabilities	$94.52M	$72.30M	$56.37M	$79.90M	$76.20M	$53.10M
YoY Change	30.73%	28.26%	-29.45%	4.86%	43.5%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	82.11M	42.10M	27.37M
Diluted Shares Outstanding	82.11M	42.10M	27.37M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $260.59 Million

About Biodesix Inc

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 217 full-time employees. The company went IPO on 2020-10-28. The firm develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Industry: Services-Medical Laboratories Peers: Bitech Technologies Corp CRYO CELL INTERNATIONAL INC CVS Health Corp Enzo Biochem Inc InfuSystem Holdings Inc Talkspace Inc Novo Integrated Sciences Inc WeCapital Holdings Inc Psychemedics Corp